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Abstract: Influencing the progression of COPD has long been an elusive goal of drug therapy. 
Directly or indirectly, this has again been investigated in two of the largest, long-term drug 
trials in COPD: Towards a Revolution in COPD Health (TORCH) and Understanding Potential 
Long-Term Impacts on Function with Tiotropium (UPLIFT®). Neither trial achieved statistical 
significance in their respective primary outcomes; however, both make considerable contribu-
tions to understanding of how the progression of COPD may be influenced. The objective of this 
article is to review the data from these different trials with a view to what can be learnt about 
the management of COPD. The long-term improvements in lung function, health-related quality 
of life, and possibly survival from the use of long-acting bronchodilators in these trials suggest 
an influence on progression of the disease. With the more optimistic view of benefits from drug 
treatment of COPD that these trials provide, a review of prescribing practices is warranted.
Keywords: bronchodilators, FEV1, fluticasone, inhaled corticosteroids, mortality, salmeterol, 
tiotropium
Burden of COPD
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality, and represents a substantial economic and social burden worldwide. Global 
prevalence of COPD in the general population has been reported to be between 7.5% 
and 10%,1,2 and is predominantly associated with smoking. In a meta-analysis of 
67 population-based studies (representing 111,000 cases of COPD from 28 countries), 
prevalence of COPD was significantly higher among smokers (15.4%) and ex-smokers 
(10.7%) than people who had never smoked (4.3%).2 Prevalence of COPD is therefore 
highest in countries where cigarette smoking is common.
Current prevalence data are likely to underestimate the true burden of COPD, 
since the disease is frequently misdiagnosed or not diagnosed until symptoms become 
clinically apparent at a more advanced stage. Of the people with COPD in Spain, for 
example, only an estimated 20% have their disease diagnosed.3 In the US, it is believed 
that between 60% and 70% of patients with reduced forced expiratory volume in 
1 second (FEV1) have never been diagnosed with COPD.4
The burden of morbidity and mortality due to COPD is predicted to increase.4 
COPD is the fourth leading cause of mortality in the US and Europe,5 and approxi-
mately 2.7 million deaths worldwide were attributable to COPD in 2000.4 Age-adjusted 
mortality due to COPD doubled between 1970 and 2002 in the US,6 and total deaths 
from COPD are projected to increase by more than 30% in the next 10 years,7 with 
notable increases predicted in women.4International Journal of COPD 2009:4 186
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It is unsurprising, therefore, that the economic costs 
attributed to COPD are substantial. For example, mean annual 
direct costs of COPD under usual clinical practice in Spain 
were calculated in a prospective study to be US$1876 per 
patient in 2003 (nearer US$3000 for severe COPD),8 which 
is approximately twice the equivalent cost reported for 
asthma.9 In the UK, direct costs were estimated to equate to 
approximately US$1900 per person per year in 1996, whilst 
in the US in the late 1990s, the annual cost of COPD was 
estimated to be US$23.9 billion, equating to approximately 
US$1500 per patient per year.10
Evolution of the disease
The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) and American Thoracic Society (ATS)/European 
Respiratory Society (ERS) consensus statements both define 
COPD as a progressive airflow limitation that is not fully 
reversible and recommend spirometry, particularly FEV1, as 
a means of diagnosing and staging COPD. Airflow limita-
tion causes air trapping and hyperinflation as ventilation rate 
increases, for example during physical effort.11 Hyperinfla-
tion causes or worsens breathlessness, as breathing becomes 
inefficient. Breathlessness encourages inactivity due to 
avoidance of exertion. Exercise capacity becomes reduced 
and deconditioning increases, which further worsens breath-
lessness on activity, and the cycle continues. Collectively, 
this contributes to reducing the patients’ health-related 
quality of life (HRQL). Exacerbations of COPD also con-
tribute to worsen these disease outcomes. Currently, there 
is no universal definition of an exacerbation, though GOLD 
define an exacerbation as “an event in the natural course of 
the disease characterized by a change in the patient’s baseline 
dyspnea, cough and/or sputum that is beyond the normal 
day-to-day variations, is acute in onset, and my warrant a 
change in regular medication in a patient with underlying 
COPD.”12
FEV1 decline as an outcome 
parameter
FEV1 decline has been considered a parameter of disease 
progression. FEV1 as a parameter of disease in individual 
patients has considerable advantages in that it is relatively 
simple to measure (with appropriate training) and is prog-
nostic of mortality, both as a single measure13–15 and in terms 
of the rate of decline.16
An increased rate of decline in FEV1 in susceptible 
smokers has been known for over 30 years,17 as has the fact 
that smoking cessation, provided it is achieved sufficiently 
early, reduces the rate of decline, though does not restore 
the FEV1 lost.18–21
However, information gained on the disease from mea-
surement of FEV1 does have limitations. FEV1 does not cor-
relate well with other markers of disease progression that are 
also prognostic of mortality,22 which question whether decline 
in FEV1 is the best marker of disease progression.23,24 Addi-
tionally, little is understood about the course through which 
FEV1 declines, which is unlikely to be linear,25 but could be 
graduated and variable depending on COPD exacerbations 
and comorbidities.26 Varying standards of spirometry and 
inter-patient variability adds to the challenge of comparing 
treatment groups with respect to the rate of decline in FEV1.
Past studies that evaluated 
FEV1 decline
Numerous specifically designed trials have failed to show 
an effect of pharmacotherapy on the rate of decline in FEV1, 
including short-acting anticholinergic (ipratropium),18 an 
antioxidant (N-acetylcysteine),27 and inhaled corticoste-
roids.28–31 Two meta-analyses on the effects of inhaled 
corticosteroids (ICS) have contradicted each other,32,33 and 
a pooled analysis suggests that ICS do not have efficacy in 
reducing the rate of decline in FEV1.34
In addition, regular physical activity has been suggested 
to reduce the rate of decline in FEV1 in smokers from a 
population study,35 however, this needs to be investigated 
in a prospective, controlled trial.
Rationale for current 
disease modification studies 
(TORCH and UPLIFT®)
A post-hoc analysis of 1-year data from two, double-blind, 
randomized, placebo-controlled trials, indicated that the long-
acting anticholinergic drug, tiotropium, may reduce the rate 
of decline in FEV1 in COPD patients.36 In addition, two ret-
rospective analyses (representing over 9700 COPD patients) 
have suggested that use of ICS, either as monotherapy or in 
combination with a long-acting β2-agonist (LABA), may 
reduce all-cause mortality in patients with COPD.37,38 Longer-
term trials were required to further investigate these effects: 
specifically an effect of LABA/ICS on all-cause mortality 
and of tiotropium on the rate of decline in FEV1.
The Towards a Revolution in COPD Health (TORCH) 
trial was a 3-year, double-blind, parallel-group, placebo-
controlled study of 6184 COPD patients randomized to 
salmeterol and fluticasone propionate, either as monotherapy International Journal of COPD 2009:4 187
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or in combination. Primary outcome was all-cause mortality 
over 3 years,39 with a post-hoc analysis on the rate of decline 
in FEV1.
40
The Understanding Potential Long-term Impacts on 
Function and Tiotropium (UPLIFT®) trial was a 4-year, 
randomized, double-blind, placebo-controlled, parallel-
group study involving 5993 patients with moderate-to-
severe COPD randomized to receive either tiotropium or 
placebo. These patients continued to receive their otherwise 
usual bronchodilator therapy. The primary outcome of the 
UPLIFT® study was rate of decline in FEV1 over 4 years.41
Summary of key findings 
from TORCH and UPLIFT®
TOrCH
TORCH did not achieve a significant decrease in mortality 
among patients treated with LABA–ICS combination therapy 
versus short-acting bronchodilators (placebo) (hazard ratio 
[HR] 0.825, 95% confidence interval [CI], 0.681–1.002; 
p = 0.052).42 However, active treatments significantly 
reduced the annual rate of exacerbations compared with 
placebo (p  0.001) and exacerbations requiring hospital 
admission were reduced with the combination therapy and 
salmeterol alone compared with placebo (p  0.03). The 
combination therapy also improved average HRQL compared 
with placebo and monotherapies over the 3-year trial period. 
Adverse event data from TORCH indicated an increased 
incidence of pneumonia among patients receiving ICS treat-
ment, both as a combination treatment and as monotherapy. 
The treatment arms containing ICS had 439 deaths compared 
with 436 deaths in the non-ICS-containing arms.
Sustained increase in lung function was observed in all 
active groups compared with placebo.42 A post-hoc analysis 
(stated as being planned before unblinding) on rate of decline 
in postbronchodilator FEV1 showed an effect of the active 
treatment groups compared with placebo.40 The rate of FEV1 
decline was 55 mL/year in the placebo (short-acting bron-
chodilators) group. In comparison, the rates of decline in the 
active treatment groups were significantly less (p  0.03) at 
39 mL/year for combined therapy and 42 mL/year for ICS 
and LABA monotherapy. The rates of decline were similar 
between the active treatment groups, with no significant 
benefit of the combination over the individual components.
UPLIFT®
UPLIFT® reported on moderate to severe COPD patients 
that received usual treatment (including LABA, ICS alone 
or in combination), and were randomized to tiotropium or 
placebo (control). These data did not show significant differ-
ences in the rate of decline in lung function or HRQL score 
between the tiotropium and control groups, but achieved a 
sustained increase in lung function and HRQL over 4 years 
(p  0.001).43 Rate of postbronchodilator FEV1 decline 
was 40 mL/year for tiotropium and 42 mL/year for the 
control group. At the end of the 4-year treatment period, the 
tiotropium group had not yet reached the level of impaired 
HRQL documented at baseline. Further, statistical significant 
increase in the proportion of patients achieving the reported 
minimal clinically significant difference of at least 4 units 
(p  0.001) occurred in the tiotropium group compared with 
the control group.
UPLIFT® demonstrated a significant reduction in the 
risk of having an exacerbation and an exacerbation leading 
to a hospitalization in the tiotropium group. Survival was 
significantly increased while patients received tiotropium and 
when including the follow-up of prematurely discontinued 
patients for the protocol-defined treatment period. However, 
the improvement in survival lost statistical significance when 
the 30-day, protocol-defined washout period was included. 
Additionally, overall cardiac and respiratory morbidity was 
reduced.
Comparison of designs
As expected for trials with different primary objectives, 
considerable differences exist between the TORCH and 
UPLIFT® trial designs and entry criteria (Table 1). Aside 
from the different primary and secondary outcomes and treat-
ment durations, a key difference is the medications that were 
permitted during the trials, other than the study drugs.39,41 
TORCH permitted maintenance use of short-acting broncho-
dilators and short courses (eg, 10 days) of oral corticosteroids 
for the treatment of exacerbations.42 Excluded were long-term 
use of oral corticosteroids, maintenance use of tiotropium 
(which was unavailable at the onset of the trial), and LABA 
and ICS, other than the study drugs.39,42 Hence, patients in 
the placebo (maintenance with short-acting bronchodilators) 
group of TORCH did not receive appropriate maintenance 
treatment according to the GOLD guidelines,44 which should 
include long-acting bronchodilators. This treatment group 
cannot, therefore, be considered as “standard” or “usual” 
care. Indeed, in part due to the positive outcomes of TORCH, 
this type of long-term, inappropriately-treated “placebo” 
comparison would no longer be considered ethical.
The UPLIFT® study permitted use of ICS, LABA, and 
their combination, but excluded inhaled anticholinergics. International Journal of COPD 2009:4 188
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Table 1 Study designs
  UPLIFT® TORCH
Duration (years) 4 3
Number of randomized patients 5993 6112
Primary endpoint Decline in lung function All-cause mortality
Secondary endpoints Decline in SGrQ score exacerbations
exacerbations SGrQ score
Mortality
run-in phase Continue therapy and adaptation (except 
inhaled anticholinergics)
withdrawal (ie, ICS, LABA and tiotropium)
Nonpermitted respiratory 
medications
Other inhaled anticholinergics Other ICS
Other LABA
Long-term use of oral corticosteroids
Tiotropium (unavailable at onset of trial, 
excluded throughout)
Frequency of control visits General: 3 months (+ first month) General: 3 months
Lung function: 6 months (+ first month) Lung function: 6 months
SGrQ: 6 months SGrQ: 6 months
reversibility test 80 µg ipratropium bromide plus 400 µg 
salbutamol
400 µg salbutamol
No exclusion due to reversibility exclusion of patients with 10% reversibility
Quality assurance of spirometry Standardized equipment Office-based spirometry
external quality assurance No additional quality assurance
external, blinded reading
evaluation of mortality vital status to 4 years vital status to 3 years
vital status to 4+ years COPD-related mortality to 3 years
Lower respiratory-related mortality On-treatment mortality
Cardiac-related mortality Primary COD and relationship with COPD 
determined by independent committee
On-treatment mortality Two interim safety analyses
Primary COD determined by 
independent committee
Definition of exacerbation An increase in, or new onset of, more 
than one respiratory symptom (cough, 
sputum, sputum purulence, wheezing, 
or dyspnea) lasting 3 days or more and 
requiring treatment with an antibiotic  
or a systemic corticosteroid
A symptomatic deterioration requiring 
treatment with antibiotic agents, systemic 
corticosteroids, hospitalization, or a combi-
nation of these
Inclusion criteria Outpatient with clinical diagnosis 
of COPD
Diagnosis of COPD
Age  40 years Age 40–80 years
Smoking history  10 pack-years Smoking history  10 pack-years
Postbronchodilatora Fev1  70% 
predictedb
Prebronchodilator Fev1  60% predictedb
Postbronchodilatora Fev1/FvC  70% Prebronchodilator Fev1/FvC  70%
Postbronchodilatorc Fev1 increase  10% 
of predicted valueb
exclusion critera Asthma or a coexisting illness that could 
preclude participation in the study 
or interfere with the study results
Asthma, non-COPD respiratory disorders, or 
other condition likely to interfere with the 
study or cause death within 3 years
(Continued)International Journal of COPD 2009:4 189
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No restrictions were imposed for medications prescribed to 
treat exacerbations. Hence, UPLIFT® closely represented 
“usual” COPD care as underlying therapy, other than inhaled 
anticholinergics, regardless of whether patients were random-
ized to receive tiotropium or placebo.
Although UPLIFT® is a placebo-controlled trial, in 
comparison to TORCH, the placebo group is better described 
as the control group. At baseline, 60% of patients in UPLIFT 
were being treated with ICS or LABA (either alone or in 
combination) and evidence suggests that more patients may 
have been prescribed these drugs during the trial.43 Hence, 
many patients in the control group in UPLIFT® could have 
been receiving similar medication to that of the active groups 
in TORCH.
Another general difference that should be high-
lighted is the disparity in patient numbers in the treatment 
groups. UPLIFT® was a two-arm study with approximately 
3000 patients in each treatment arm;43 TORCH was a 
four-arm study with approximately 1500 patients in each 
treatment arm.42 Both trials were designed to be sufficiently 
powered for the primary outcome; however, the difference 
in patient numbers could be a general consideration when 
comparing some secondary and subanalyses.
Unlike UPLIFT®, the TORCH study excluded patients 
based on acute reversibility to short-acting bronchodilators 
exceeding 10% of predicted (Table 1).39,41 Reversibility to 
short-acting bronchodilators is frequently used as a means for 
excluding asthmatic patients from COPD studies; 44 however, 
several studies (including data from UPLIFT®) indicate that 
such practice could also exclude patients with COPD.45–47 
Repeat testing of the same patients for reversibility to bron-
chodilators shows considerable variability in magnitude 
of response. This difference in exclusion, along with the 
less severe postbronchodilator FEV1 inclusion criterion in 
UPLIFT®, may have accounted for the high proportion of 
GOLD stage II patients in the UPLIFT® study. Addition-
ally, acute response to short-acting β2-agonist identify a 
subgroup of COPD patients more likely to respond to ICS 
with a significant increase in FEV1.48 Therefore, excluding 
reversible patients in TORCH may have selected a popula-
tion less likely to present positive outcomes with LABA 
and ICS therapy.
With respect to postbronchodilator FEV1 measurements 
during the trials, UPLIFT® included use of the anticholinergic, 
ipratropium, as well as the short-acting β2-agonist (SABA), 
salbutamol (albuterol), that was also used in TORCH. This 
was to insure maximal bronchodilation and, thereby, mini-
mize the influence of bronchomotor tone on measurement of 
the rate of decline in FEV1. This difference between the trials 
may have little relevance beyond assessment in rate of decline 
except in making the actual magnitude of postbronchodilator 
FEV1 less comparable between the trials.
Despite the differences in the primary outcome (and 
hence, statistical power) and study designs, both UPLIFT® 
and TORCH are of sufficient size and duration to provide 
important insights into the natural course of COPD and the 
effect of pharmacologic treatment.
Comparison of patients
Demographic characteristics were similar between the two 
study populations. In both trials, the mean age of patients was 
65 years and 75% of patients were male, which is typical of 
the demographic of treated patients with COPD. Mean body 
mass index (BMI) for both studies was also similar (25 and 
26 for TORCH and UPLIFT®, respectively). Mean dura-
tion of COPD was approximately 10 years in the UPLIFT® 
Table 1 (Continued)
  UPLIFT® TORCH
Use of oxygen therapy for 12 hours/day A requirement for oxygen therapy  
for 12 hours/day
respiratory infection or exacerbation  
of COPD within 4 weeks of screening  
or during the run-in period
exacerbation requiring systemic oral 
corticosteroid therapy and/or hospitalization 
during the run-in period
recent history of myocardial infaction  
or heart failure
Current use of oral corticosteroid therapy
   History of thoractomy with pulmonary 
resection
History of lung-volume reduction surgery 
and/or lung transplant
aAfter supervised administration of 80 µg ipratropium (four actuations) followed by 400 µg salbutamol (four actuations) 60 minutes later and the test was 30 minutes after 
the salbutamol dose (test 90 minutes after ipratropium); beuropean Community for Coal and Steel (eCCS) criteria; 84 c400 µg salbutamol.
Abbreviations: Fev1,  forced expiratory volume in 1 second; FvC,  forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; SGrQ, St. George’s 
respiratory Questionnaire; COD, cause of death.International Journal of COPD 2009:4 190
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study; however, similar statistics were not provided for the 
TORCH trial.
There were fewer current smokers in UPLIFT® (approxi-
mately 30%) compared with 43% in TORCH. Entry criteria 
were the same with respect to 10 pack-years and mean 
pack-years were similar between the two studies (around 
48 pack-years). However, smoking cessation programs were 
offered to all patients in UPLIFT® prior to randomization 
and smoking status was balanced between the two groups 
following randomization.41,43 In contrast, patients were 
stratified at randomization according to smoking status in 
TORCH.39,42 Since smoking cessation is known to influence 
the rate of decline in lung function, this difference could 
influence the relative rate of decline observed between the 
two studies.
Mean prebronchodilator FEV1 was similar between the 
two trials (approximately 1.1 L). Mean baseline postbron-
chodilator FEV1 (absolute and percent predicted) was higher 
in UPLIFT® (around 47% of predicted) than in TORCH 
(around 44% of predicted). In contrast, the mean baseline 
FEV1/forced vital capacity (FVC) was lower in UPLIFT® 
(around 43% of predicted) compared with TORCH (around 
48% of predicted). However, these differences between 
the trials may in part be due to the different short-acting 
bronchodilator regimen used (see above), which makes 
comparisons difficult.
In both studies, HRQL was measured by total score on 
the St George’s Respiratory Questionnaire (SGRQ). Baseline 
SGRQ score differed between the two trials by approxi-
mately 3 units, with UPLIFT® having the lower (less severe) 
score. While this may not be considered as clinically relevant 
(ie, 4 units), it does numerically support the suggestion 
from the lung function data that patients in the UPLIFT® trial 
were skewed towards less severe compared with patients in 
TORCH. Indeed, 46% of patients in UPLIFT® were reported 
to have GOLD stage II (moderate) COPD (three patients 
with GOLD stage I were enrolled, recognized as a protocol 
violation, but data were included).43 Similar statistics were 
not reported in TORCH.
Comparison of the TORCH 
and UPLIFT® decline in lung function
rate of decline in Fev1
The data from the post-hoc analysis of TORCH suggest 
that all three active groups reduce the rate of decline in 
postbronchodilator FEV1, the only spirometric parameter 
reported.40 Adjusted rates of decline in FEV1 were -42 ± 
3 mL/year for salmeterol alone and fluticasone propionate 
alone, -39 ± 3 mL/year for salmeterol/fluticasone com-
bination, and -55 ± 3 mL/year for placebo (short-acting 
bronchodilators) (Figure 1); this corresponded to reduc-
tions in the rate of FEV1 decline versus placebo by 13 ± 
4 mL/year each (95% CI, 5–22, p = 0.003) for salmeterol 
alone and fluticasone alone, and 16 ± 4 mL/year (95% CI, 
7–25; p  0.001) for the salmeterol/fluticasone combination. 
No significant differences exist between the combination and 
individual drugs alone. Nearly 18% of patients randomized to 
the placebo group in TORCH withdrew before contributing 
an FEV1 value. The TORCH authors commented that this 
could have underestimated the decline in lung function in 
the placebo group, with those patients who withdrew having 
Primary Outcome Post-hoc Analysis
UPLIFT® (4 years) TORCH (3 years)
Control Tiotropium Placebo Salmeterol Fluticasone Combination
“Ceiling”: Estimated annual decline in FEV1 healthy subjects (~30 mL)
0
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Figure 1 Change in rate of decline in Fev1 in UPLIFT® and TOrCH, including ceiling effect (possible rate of decline in healthy individuals). Data from the individual trials have 
been placed on the same axes for illustrative purposes only and do not represent directly comparable data between the trials.
Notes: *p = 0.003 vs placebo; †p  0.001 vs placebo.
Abbreviations: Fev1, forced expiratory volume in 1 second.International Journal of COPD 2009:4 191
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a steeper rate of decline. However, in an editorial, Suissa 
suggested that the patients who withdrew from the study 
could have had the lowest FEV1 values at the beginning of 
the study and, therefore, the “regression to the mean” could 
have exaggerated the rate of decline since these were the 
patients with the slowest decline in FEV1.49
The data from the TORCH post-hoc analysis is valuable, 
but adds to the ambiguity of understanding. Inhaled 
Steroids in Obstructive Lung Disease in Europe (ISOLDE) 
study was specifically designed to investigate the effect 
of fluticasone priopionate on the rate of decline in FEV1 
but suggested there was no additional effect above that 
achieved with placebo (rates of decline in FEV1 in ISOLDE 
were -50 ± 4 vs -59 ± 4 mL/year for the active vs short-
acting bronchodilators [placebo] groups; p = 0.16).31 The 
effect of ICS on the rate of decline in FEV1 were reported 
from two meta-analyses of randomized placebo-controlled 
trials 1 year in length.32,33 The majority of the same trials 
were included in both meta-analyses. Sutherland et al 
reported significantly lower rates of decline in FEV1 with ICS 
than placebo (-7.7 mL/year vs placebo; p = 0.02)32 whereas 
Highland et al reported no significant difference (-5 mL/year 
vs placebo; p = 0.11).33 Results from a pooled analysis of 
seven studies (total N = 3911) have also suggested that ICS 
do not affect the rate of decline in FEV1 (–0.01% vs placebo 
from months 6–36, p = 0.86).34 As rate of FEV1 decline was 
a tertiary endpoint in TORCH, it is sensible to view the data 
from this trial as hypothesis generating only; they continue 
to suggest the hypothesis that FEV1 decline in COPD can be 
reduced by pharmacotherapy.
Additional support for this hypothesis comes from a 
post-hoc, retrospective analysis of two 1-year trials with 
tiotropium. These double-blind, placebo-controlled, random-
ized trials comparing tiotropium (total N = 971) with placebo 
showed promising improvement in the rate of decline of 
FEV1. The mean decline in trough (premedication) FEV1 
was 46 mL/year lower between Days 8 and 344 (p = 0.005) 
and 40 mL/year lower between Days 50 and 344 (p = 0.036) 
versus short-acting bronchodilators (placebo).36 These data, 
along with the TORCH post-hoc data, suggest that FEV1 
decline can be reduced by effective treatment with mainte-
nance long-acting bronchodilator therapy alone.
UPLIFT® was specifically designed to prospectively 
test the reduction in decline in pre- and post-bronchodilator 
FEV1 with tiotropium in a controlled, 4-year study. UPLIFT® 
showed no difference between tiotropium and the control 
group in terms of rate of decline in FEV1 (calculated 
from Day 30 until end of study) for both components of 
the primary outcome: differences were 2 mL/year when 
measured postbronchodilator (-40 ± 1 vs -42 ± 1 mL/year; 
p = 0.21; Figure 1) and 0 mL/year when measured prebron-
chodilator (-30 ± 1 mL/year for each group; p = 0.95).43 
Similar data were also reported for tiotropium versus control 
for the secondary endpoints of pre- and postbronchodila-
tor rates of decline in FVC (-43 ± 3 vs -39 ± 3, p = 0.30 
and -61 ± 3 vs -61 ± 3, p = 0.84, respectively) and slow 
vital capacity (SVC) (-47 ± 3 vs -41 ± 3 mL/year, p = 0.11 
and -66 ± 3 vs -65 ± 3, p = 0.79, respectively). In isola-
tion, and since this was a specifically designed trial, these 
data would seemingly suggest that pharmacotherapy cannot 
reduce the rate of decline in lung function; however, this 
may not be the case.
Considering the UPLIFT® and TORCH data together, 
and in the context of other studies, may indicate an important 
insight into the decline in FEV1. The rate of decline observed 
in the control arm of UPLIFT® (–42 mL/year) is similar to that 
for the active monotherapy groups in TORCH (-42 mL/year). 
The active group in UPLIFT® produced a similar rate of 
decline to the TORCH salmeterol/fluticasone combination 
group (-40 vs -39 mL/year). As the TORCH investigators 
indicated, the TORCH placebo group was similar to the 
placebo groups reported in previous trials.19,20,27,28,30,31,34 
However, the UPLIFT® control group included patients 
treated with LABA and ICS (72%, 74%, and 46% received 
LABA, ICS, or LABA/ICS combination, respectively), 
therefore, could be considered a more “active” control group 
than the TORCH placebo. It is possible that tiotropium was 
unable to further reduce this decline due to a ceiling effect 
(ie, medications can only reduce the rate of decline to a 
certain amount since there is a basal rate of decline in FEV1 
in normal individuals) (Figure 1).
The UPLIFT® authors suggest some preliminary evidence 
to support the above hypothesis of a ceiling effect. Subgroup 
analysis of the 1554 patients not receiving ICS or LABA at 
baseline showed a significantly lower postbronchodilator rate 
of decline in FEV1 for tiotropium versus control (40 ± 3 vs 
47 ± 3 mL/year; p = 0.046).43 However, this needs further 
investigation, since interpretation is currently difficult. As 
such, the greater effect size seen in TORCH compared with 
UPLIFT® may be driven by the less active treatment received 
by the placebo group in the TORCH study versus the control 
group in the UPLIFT® study.
In previous studies, the rate of decline in FEV1 seen 
in both active and placebo groups has been higher than 
those seen in UPLIFT® and TORCH. For example, in the 
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Pulmonary Disease (EUROSCOP),28 Bronchitis Randomized 
on NAC Cost-Utility Study (BRONCUS),27 and ISOLDE 
study,31 declines in postbronchodilator FEV1 were between 
44 and 57 mL/year and 47 and 69 mL/year in the active and 
placebo (short-acting bronchodilators) groups, respectively. 
Therefore, results from TORCH and UPLIFT® suggest that 
all treatments, including maintenance therapy with long-
acting bronchodilators, can reduce the rate of decline in FEV1, 
with the impact on this decline being dependent on the type 
of agent or combination of agents received.
Subgroup analyses of UPLIFT® and TORCH also provide 
us with some insight into patient characteristics that may 
affect the rate of FEV1 decline (Table 2). There are some 
consistencies in the results seen in the studies. For instance, 
seemingly contrary to previous models of decline in lung 
function in COPD,17 decline is more rapid in younger patients 
(aged  55 years) than older patients. BMI was associated 
with the rate of FEV1 decline, with a higher BMI seemingly 
being beneficial in both trials. Low BMI and fat-free mass 
are known independent predictors of disease severity and 
mortality; 50,51 however, this association with rate of FEV1 
decline is a novel finding. Although the rate of FEV1 decline 
appears to be more rapid in men than women, percentage 
changes in rate of decline in FEV1 were similar between the 
sexes, suggesting that this may be associated with airway 
size rather than a true difference in rate of disease progres-
sion. Geographical region was also associated with the rate 
of decline; however, with the exception of a lower rate of 
decline in Asia, this was not consistent between the studies 
and, therefore, could also be an artefact of airway size. In 
UPLIFT®, the rate of FEV1 decline was more rapid in earlier 
stages of COPD (GOLD stage II vs stages III and IV); 
importantly, there is some suggestion that tiotropium may 
positively affect the rate of decline in these earlier stage 
patients (p = 0.02), although further supportive evidence is 
required to confirm this observation.
Absolute changes in Fev1
Both trials show that improvements in FEV1 are sustained 
over a considerable period after initiation of treatment. In 
UPLIFT®, lung function was significantly better with tiotro-
pium than control at all measured time points throughout the 
trial (difference in mean FEV1 values ranged between 87 and 
103 mL, and 47 and 65 mL for pre- and postbronchodilator 
measurements, respectively; p  0.001). In the tiotropium 
group, mean FEV1 values returned to baseline level after 
around 24 months (postbronchodilator) and 48 months 
(prebronchodilator), whereas mean FEV1 values in the 
control group returned to baseline after only around 12 and 
10 months, respectively. Similar patterns for postbronchodi-
lator FEV1 values were observed in the TORCH study, with 
a reported difference in mean change from baseline over the 
3-year trial period compared with placebo of 93 mL with the 
combination, 42 mL with salmeterol monotherapy and 47 mL 
with fluticasone monotherapy (all p  0.001, as was the 
comparison between the combination and monotherapies). 
Mean postbronchodilator FEV1 values returned to baseline 
level after around 30 months in the combination group, 
compared with approximately 18 months in the monotherapy 
groups and approximately 6 months in the placebo group. 
Prebronchodilator mean FEV1 values were not reported. In 
the ISOLDE study, the mean FEV1 (postbronchodilator) was 
also significantly higher in the ICS group than the placebo 
group (by 76 mL and 100 mL at the 3- and 36-month time 
points, respectively; p  0.001).31
An interesting phenomenon in UPLIFT® was the 
improvement in postbronchodilator spirometry values. The 
expected “maximal bronchodilation” produced by the high-
dose salbutamol and ipratropium may have been expected 
to cause patients in the two treatment groups to be equal in 
terms of bronchodilation capacity postbronchodilator. How-
ever, postbronchodilator FEV1 and FVC values were higher 
with tiotropium than control at all time points. This finding 
is difficult to interpret given the complexity from the use of 
three bronchodilators (two of which were anticholinergics) 
and factors other than airway diameter that could affect 
spirometry.
Overall, evidence gained from UPLIFT®, TORCH, and 
previous, smaller studies indicate that, while it is difficult 
to conclude that long-acting bronchodilators significantly 
reduce the rate of decline in lung function, these agents 
certainly improve lung function. Therefore, they may delay 
disease progression even if they do not affect the disease 
course itself. This is contrary to smoking cessation, which, 
provided it occurs sufficiently early in the course of COPD, 
can reduce the rate of decline in FEV1 but does not restore 
lung function that has been lost.17,21 As pharmacotherapy in 
COPD can improve lung function, there is an argument for 
administering pharmacotherapy at a similarly early stage 
in COPD.
Comparison of exacerbation data
Exacerbations are part of the natural course of COPD52 
and are responsible for the morbidity and mortality of this 
disease.26,53–55 Exacerbations are associated with reduced 
quality of life56–58 and increased mortality.59 They are also the International Journal of COPD 2009:4 193
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Table 2 Mean (Se) rate of decline (mL/year) in postbrochodilator Fev1 by subgroup
UPLIFT® TORCH40
  Control Tiotropium Difference p value All patients p value
Age (years) 0.57a 0.001b
  55 54 (4) 47 (3) -6 (5) 0.21 51.7 (4.3)
  55, 65 48 (2) 45 (2) -3 (3) 0.29 51.3 (2.6)
  65, 75 35 (2) 36 (2) 1 (3) 0.84 39.5 (2.4)
  75 35 (4) 29 (4) -6 (6) 0.35 36.7 (4.7)
Smoking status 0.90a 0.001b
  Former 38 (2) 36 (2) -2 (2) 0.34 36.6 (2.1)
  Current 52 (3) 50 (2) -4 (4) 0.45 55.0 (2.3)
Regionc 0.81a 0.001b
  Asiac 31 (6) 26 (5) -5 (8) 0.54 30.7 (4.2)
  eastern europe 43 (3) 45 (3) 2 (4) 0.61 38.2 (3.3)
  Latin America 44 (5) 42 (5) -2 (7) 0.82 n/a
  US 39 (3) 35 (3) -4 (4) 0.34 49.4 (3.4 )
  western europe 45 (2) 41 (2) -4 (3) 0.22 50.9 (2.8)
  Other n/a n/a n/a n/a 48.4 (4.2)
Gender 0.63a 0.027b
  Male 43 (1) 41 (1) -2 (2) 0.38 46.6 (1.8)
  Female 39 (3) 35 (3) -4 (4) 0.29 38.5 (3.2)
GOLD Stage 0.08a n/p
  I/II 49 (2) 43 (2) -6 (3) 0.02 n/p
  III 38 (2) 39 (2) 0 (3) 0.87 n/p
  Iv 23 (5) 32 (5) 9 (7) 0.24 n/p
BMId 0.77a 0.001b
  20 55 (4) 53 (4) -1 (6) 0.85 51.1 (4.4)
  20, 25 49 (2) 44 (2) -5 (3) 0.12 50.2 (2.5)
  25, 30d 37 (2) 36 (2) -2 (3) 0.59 42.1 (2.9)
  30d 34 (3) 34 (3) 0 (4) 0.98 35.1 (3.2)
Concomitant medication
  LABA 0.57a n/p
    Yes 44 (2) 40 (2) -4 (3) 0.22 n/p
    No 41 (2) 39 (2) -2 (2) 0.54 n/p
  ICS 0.68a n/p
    Yes 45 (2) 42 (2) -3 (3) 0.27 n/p
    No 40 (2) 38 (2) -2 (2) 0.47 n/p
  LABA + ICS 0.71a n/p
    Yes 43 (2) 42 (2) -2 (3) 0.52 n/p
    No 41 (2) 38 (2) -3 (3) 0.26 n/p
  Anticholinergics 0.69a n/p
    Yes 42 (2) 39 (2) -3 (3) 0.22 n/p
    No 42 (2) 41 (2) -2 (3) 0.60 n/p  
aSubgroup by treatment interaction; beffect of covariate on slopes of all patients pooled regardless of study drug group; cGeographical descriptions of different trials. Pacific 
countries were combined with Asia in TOrCH; dBMI, weight (kg)/[height (m)]2. 29 was the cut-off for TOrCH.
Abbreviations: n/a, not applicable; n/p, not published; GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index; ICS, inhaled corticosteroids; 
LABA, long-acting β2-agonists.International Journal of COPD 2009:4 194
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main driver of costs in COPD.60 Unsurprisingly, therefore, 
reducing exacerbations is a key goal of COPD treatment.44
There is inconsistency in how exacerbations are defined 
and analyzed, which makes it difficult to compare data on 
exacerbations between trials.61 In UPLIFT®, an exacerbation 
was defined as “an increase or new onset of more than one of 
the following respiratory symptoms (cough, sputum, sputum 
purulence, wheezing, dyspnea) with a duration of 3 or more 
days requiring treatment with an antibiotic and/or systemic 
(oral, intramuscular or intravenous) steroid”.41 Exacerbations 
were categorized as mild (treated at home without seeing a 
healthcare provider), moderate (visit with healthcare provider, 
at home or as outpatient), or severe (requiring hospitalization 
for 24 hours). In TORCH, exacerbations were defined as 
symptomatic deterioration requiring treatment with systemic 
corticosteroids and/or antibiotics (moderate exacerbation) or 
hospitalization (severe exacerbation).39,42
In UPLIFT®, compared with control, tiotropium significantly 
delayed time-to-first exacerbation (16.7 vs 12.5 months) 
and time-to-first hospitalization for exacerbations (lower 
risk of hospitalization; HR, 0.86 [95% CI, 0.78–0.95]; 
p = 0.002) (Table 3).43 Exacerbations requiring hospitaliza-
tion were infrequent (0.15 vs 0.16 per patient-year), which 
may explain why any difference between tiotropium and 
placebo groups was not statistically significant (p = 0.34). 
Tiotropium also reduced the mean number of exacerba-
tions by 14% (rate per patient-year, 0.73 vs 0.85; HR, 0.86 
[95% CI, 0.81–0.91]; p  0.001), and reduced the number 
of days with exacerbations (13.64 vs 12.11; HR, 0.89 [95% 
CI, 0.83–0.95]; p = 0.001) compared with control. These 
results were consistent with those from other shorter dura-
tion studies in which tiotropium has been shown to reduce 
the number of exacerbations by 20% to 50%,62–66 number 
of exacerbation days by 31% to 50%,63,65,66 number of 
Table 3 exacerbations
UPLIFT® (4 years) TORCH (3 years)
  Control Tiotropium Placeboa Salmeterol Fluticasone Combination
Time to first exacerbation





  Hazard ratio (95% CI), vs control – 0.86
(0.81–0.91)
    Hazard ratio (95% CI) for first 





  exacerbations/patient-yearb 0.85 (0.02) 0.73 (0.02) 1.13 0.97 0.93 0.85








    exacerbations requiring  
hospitalization/patient-yearb
0.16 (0.01) 0.15 (0.01) 0.19 0.16 0.17 0.16








    exacerbations requiring systemic 
corticosteroids/patient-year
Not published 0.80 0.64 0.52 0.46






  exacerbation days/patient-yearb 13.64 (0.35) 12.11 (0.32) Not published
  rate ratio (95% CI), vs control – 0.89
(0.83–0.95)
  Hospitalization days/patient-yearb 3.13 (0.17) 3.17 (0.17) Not published















aShort-acting bronchodilators were permitted throughout the study; bMean (Se); cNot statistically significant.
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hospitalizations due to exacerbations by 20% to 30%67 and 
time-to-first exacerbation.62,63,65 Compared with short-acting 
bronchodilators, associated healthcare resource utlilization 
was also consistently reduced with tiotropium in these earlier 
studies.63,65,67
Rates of moderate or severe exacerbations per patient-year 
were reduced in all active groups in the TORCH study (0.85, 
0.93, 0.97, and 1.13 for combination, fluticasone only, 
salmeterol only, and placebo groups, respectively; p  0.001 
vs placebo); significantly lower rates were also seen with 
the combination group vs salmeterol (p = 0.002) and fluti-
casone (p = 0.02) monotherapy groups (Table 3).42 Both the 
combination and salmeterol groups reduced, by the same 
magnitude, the rate of exacerbations requiring hospitaliza-
tion versus placebo (0.16 and 0.16 vs 0.19 per patient-year; 
p = 0.03 and p = 0.02, respectively).42 No data on time-to-
first exacerbation, number of days with exacerbations, or 
number of days in hospital in TORCH were published. These 
data confirm those from a previous 1-year study in which 
salmeterol/fluticasone combination and the single agents 
have reduced the frequency of exacerbations by 25% and 
19% to 20%, respectively.68
It is possible to draw some comparisons between the 
UPLIFT® and TORCH findings despite the difference in 
counting and analyses. There were significant improvements 
in multiple measures of exacerbations with the active groups 
in both trials. In terms of rates of exacerbations per patient-
year, these were slightly lower with tiotropium compared 
with the active treatment groups in TORCH (0.73 vs 
0.85–0.97). Similar to the results for lung function decline, 
the exacerbation rate (0.85 per patient-year) in the placebo 
group in UPLIFT® was closer to the rates seen in the active 
treatment groups in TORCH than the TORCH placebo group 
(exacerbation rate of 1.13 per patient-year). Again, the fact 
that the UPLIFT® placebo group included patients treated 
with LABA and ICS, and the postulated “ceiling effect” 
described above, may explain why there was a relatively 
low rate of exacerbation in this group compared with the 
TORCH placebo group and, therefore, why the extent of 
the improvement beyond this (14%) with tiotropium was 
lower than the 25% improvement seen in TORCH (Figure 2). 
This may also suggest a benefit from a triple combination of 
tiotropium, LABA and ICS.
Reduction in exacerbations and exacerbations leading to 
hospitalization is one of the mechanisms that may explain a 
reduction in mortality in both trials. The mechanism of the 
link between exacerbations and mortality could be associ-
ated with hyperinflation, which is also related to mortality.69 
Hyperinflation is likely to worsen during exacerbations of 
COPD. Tiotropium, salmeterol, and the combination of 
salmeterol and fluticasone are effective in reducing hyper-
inflation and improving exercise capacity.70–74
Comparison of HrQL data
Both trials evaluated HRQL using SGRQ. This is one of 
the most widely used instruments for measuring HRQL 
in respiratory patients, and has been used extensively in 
therapeutic evaluation studies.
Comparing the results of UPLIFT® and TORCH (Table 4), 
all treatments failed to achieve a mean clinical significance at 
the end of the trials, ie, a mean reduction of 4 or more units 
on the SGRQ total score. However, all treatments achieved 
statistical significance. Statistically significant differences in 
mean change in SGRQ total score were observed at all time 
points throughout the UPLIFT® trial, in favor of tiotropium. 
In TORCH, time point data were not reported; instead, mean 
changes in SGRQ total score were averaged over 3 years, 
which demonstrated a statistically significant improvement 
in the combination therapy group compared with the placebo 
and monotherapy groups.
In addition, a significantly higher proportion of patients 
in the tiotropium group than the control group in UPLIFT® 
had an improvement of 4 or more units from baseline 
at 1 year (49% vs 41%), 2 years (48% vs 39%), 3 years 
(46% vs 37%), and 4 years (45% vs 36%; p  0.001 for all 
comparisons). These data compare favorably with a previous 













































Figure 2 Change in exacerbation rates by the active treatment groups in UPLIFT® and 
TOrCH. Data from the individual trials have been placed on the same axes for illustrative 
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long-term study of tiotropium in which the percentages of 
patients with a clinically meaningful response after 1 year 
were 49% and 30% in the tiotropium and placebo groups, 
respectively.75 The proportion of patients in TORCH 
achieving a change of at least 4 units on the SGRQ total 
score was not reported, preventing further comparison 
between the two studies.
Similar to the lung function results, no between-group 
differences were observed in UPLIFT® in the rate of 
decline in SRGQ scores (Table 4). The permitted use of 
ICS, LABA, and their combinations as rescue medica-
tion, together with the unrestricted use of medications to 
treat exacerbations in UPLIFT®, may have narrowed any 
between-treatment improvements in HRQL. As previously 
stated, maintenance treatment with inhaled fluticasone 
alone affected the rate of deterioration in SGRQ in the 
ISOLDE trial.76 Rate of decline in SRGQ scores has not 
yet been reported from TORCH.
Comparison of mortality data
A key goal of COPD therapy is to reduce mortality.44 In 
UPLIFT®, mortality data have been reported for two intent-
to-treat 4-year “vital status” analyses for which at least 
45 months follow-up was available, including patients who 
had discontinued, and for patients “on treatment”.43 These 
analyses were a) from Days 1–1440 (planned 4 years of 
study treatment), b) the protocol-defined on-treatment period 
of 1470 days (1440 days planned treatment plus 30 days 
follow-up), and c) the first to actual last day of treatment 
plus 30 days follow-up. The difference in 4-year all-cause 
mortality between the tiotropium and placebo groups was 
not statistically significant for the protocol-defined 1470-day 
vital status analysis (p = 0.09) (Table 5); a significant 
difference between groups was observed, however, according 
to both the 1440-day analysis and the on-treatment analysis. 
A possible reason for the difference between the 1470-day 
and the other analyses is that data were received on only 75% 
of patients for the former compared with, for example, 95% of 
patients for the 1440-day analysis. A recent meta-analysis 
of safety with tiotropium has addressed a composite vari-
able of cardiovascular death, non-fatal myocardial infarc-
tion or non-fatal stroke.77 The results of this meta-analysis is 
discussed later in the safety and tolerability section.
In TORCH, mortality data was on an intent-to-treat basis 
and was analyzed from Day 1 to the end of the treatment 
period (3 years). Unlike UPLIFT®, the follow-up period 
(15 days in TORCH; 30 days in UPLIFT®) was not included. 
There was no statistically significant difference in the 3-year 
all-cause mortality rate between the salmeterol/fluticasone 
combination group and the placebo group (p = 0.052) 
(Table 5). A slightly higher mortality rate was observed in 
the salmeterol-only arm (13.5%) than the combination arm 
(difference not significant vs combination arm [12.6%] or pla-
cebo [15.2%]). In the fluticasone-only arm, the mortality rate 
(16%) was actually higher numerically than placebo and sig-
nificantly higher than in the combination arm (p = 0.007).
Although the UPLIFT® and TORCH studies are not 
directly comparable, Figure 3 provides a comparison 
similar to Figure 1. The results of UPLIFT® showed that 
a long-acting bronchodilator (tiotropium) appeared to 
have an impact on mortality. Consistent with this, after 
factorial analysis, some authors suggested that the effect 
on mortality observed in the combination arm in TORCH is 
entirely due to the long-acting bronchodilator, ie, the LABA 
(salmeterol).49,78 Indeed, a higher mortality rate was seen in 
the fluticasone-only arm compared with the combination arm 
and with placebo (difference vs placebo was not significant). 
The role of ICS in long-term treatment in COPD is still 
under debate.79,80
Overall, the results from UPLIFT® and TORCH suggest 
that both tiotropium and the salmeterol/fluticasone combina-
tion may reduce the risk of mortality.
Table 4 SGrQ total score
UPLIFT® (4 years) TORCH (3 years)
  Control Tiotropium Placebo Salmeterol Fluticasone Combination
% with 4 unit change at end of trial 36 45 Not published
Mean (95% CI) difference from control  









rate of decline, units/yearc 1.21 (0.09) 1.25 (0.09) Not published
  ∆ from control – 0.04 (0.13)b
Notes: aUPLIFT® also published the range of mean differences from placebo over the 4-year trial as -3.3– -2.3 (p  0.001); bNot statistically significant; cMean (Se).
Abbreviations: SGRQ, St. George’s Respiratory Questionnaire; CI, confidence interval.International Journal of COPD 2009:4 197
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Table 5 Mortality
UPLIFT® (4 years) TORCH (3 years)
  Control Tiotropium Placeboa Salmeterol Fluticasone Combination
Percentage of deaths (%)
  4-year follow-up 16.3 14.4 Not applicable
  Hazard ratio (95% CI), vs control – 0.87
(0.76–0.99)
  4-year plus 30 days follow-up 16.5 14.9 Not applicable
  Hazard ratio (95% CI), vs control – 0.89b
(0.79–1.02)
  On treatment plus 30 days follow-up 13.7 12.8 Not applicable
  Hazard ratio (95% CI), vs control – 0.84 
(0.73–0.97)
  3-year follow up Not applicable 15.2 13.5 16.0 12.6






aShort-acting bronchodilators were permitted throughout the study; bNot statistically significant; cAdjusted for interim analyses.





























SFC vs Placebo (3 years) Tiotropium vs Control (4 years)
HR = 0.825 (95% Cl, 0.681–1.002) HR = 0.89 (95%  Cl, 0.79–1.02)

























Figure 3 Comparison of selected mortality data presented in the TOrCH and UPLIFT® primary publications.40,43 Data from the individual trials have been placed on the same 
axes for illustrative purposes only and do not represent directly comparable data between the trials.
Abbreviations: CI, confidence interval; HR, hazard ratio; SFC, salmeterol and fluticasone in combination.International Journal of COPD 2009:4 198
Miravitlles and Anzueto Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Table 6 The most frequently occurring adverse events categorized by ranges of incidence rate per year
UPLIFT® (4 years) TORCH (3 years)40
  Control Tiotropium Placebo Salmeterol Fluticasone Combination
Incidence rate 
per year, range 
(actual)












Upper rTI (0.09) Nasopharyngitis 
(0.09)
Headache (0.08) Upper rTI (0.08)
0.06–0.07 – – – Headache (0.06) Pneumonia (0.07) Pneumonia (0.07)
Headache (0.06)
0.04–0.05 Dyspnea (0.05) Pneumonia (0.05) Bronchitis (0.05) Bronchitis (0.05) Bronchitis (0.05) Bronchitis (0.05)






Back pain (0.04) Headache (0.05)
Nasopharyngitis 
(0.04)
Dyspnea (0.04) Back pain (0.04) Back pain (0.04) Sinusitis (0.04) Back pain (0.04)
  Upper rTI (0.04)       Cough (0.04) Sinusitis (0.04)
Abbreviations: COPD ex, chronic obstructive pulmonary disease exacerbations; rTI, respiratory tract infection.
Comparison of safety and tolerability data
The proportions of patients experiencing adverse events 
(AEs) were similar between UPLIFT® and TORCH (ranges 
across groups and trials were 89% to 93%, 40% to 52%, and 
18% to 25% for AEs, serious AEs [SAEs], and events leading 
to withdrawal, respectively).42,43 Side effects were generally 
those expected from the class of drugs used. In UPLIFT®, 
tiotropium reduced the rate of cardiac (including congestive 
heart failure and myocardial infarction) and lower respiratory 
(including respiratory failure and dyspnea) SAEs compared 
with control (p  0.05); there was no significant difference 
in the incidence of stroke between tiotropium and control. 
This finding contrasts with the suggestion from a recent 
meta-analysis that anticholinergics are associated with 
an increase in risk of cardiovascular events,77 though the 
results of UPLIFT® are consistent with a pooled analysis 
of patient-level data from 19 other trials with tiotropium.81 
The most frequently occurring AE in all groups of both 
trials was COPD exacerbations (Table 6). Fluticasone-
containing treatment was associated with an increased 
probability of having pneumonia in TORCH. Incidences of 
pneumonia were 19.6%, 18.3%, 13.3%, and 12.3% in the 
combination, fluticasone-only, salmeterol-only, and placebo 
arms, respectively, with significant differences between 
the combination and fluticasone-only arms versus placebo 
(p  0.001) and combination versus salmeterol-only arms 
(p  0.001). There were no significant ocular or bone-related 
safety signals observed with active TORCH treatments. In 
UPLIFT®, dry mouth and constipation were observed, two 
side effects that are consistent with the known safety profile 
for tiotropium.
Overall, the results from UPLIFT® confirm the favorable 
safety profile with tiotropium.81 No strong safety signals were 
seen with salmeterol monotherapy in TORCH; the increased 
risk of pneumonia with fluticasone-containing regimens 
mirrors previous studies.82,83
Conclusions
Although neither UPLIFT® nor TORCH reached their 
primary endpoints, these trials have revealed the impact 
of long-term bronchodilators in the treatment of COPD. 
Long-acting bronchodilators in the form of tiotropium and 
salmeterol (in combination with fluticasone propionate) 
can actually improve lung function and may delay progres-
sion of COPD, thus positively affecting disease prognosis. 
Mortality may also be reduced and HRQL improved. Despite 
international and national guidelines recommending long-
acting bronchodilators for COPD, these agents are currently International Journal of COPD 2009:4 199
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under-prescribed. UPLIFT® and TORCH results support an 
urgent change in prescribing practices.
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